

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number  
WO 02/062402 A1(51) International Patent Classification<sup>7</sup>: A61L 12/08,  
27/02, 27/14, A45C 11/00, G02B 1/04, G02C 7/04

(21) International Application Number: PCT/US01/50582

(22) International Filing Date:  
21 December 2001 (21.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/257,317 21 December 2000 (21.12.2000) US(71) Applicant: JOHNSON & JOHNSON VISION CARE,  
INC. [US/US]; 7500 Cenurion Parkway, Suite 100, Jack-  
sonville, FL 32256 (US).(72) Inventors: VANDERLAAN, Douglas, G.; 8114  
Parkridge Circle S., Jacksonville, FL 32211 (US).  
MEYERS, Ann; 3134 Misty Creek Lane, Jacksonville,  
FL 32216 (US). BROWN-SKROBOT, Susan; 8707  
Rolling Brook Lane, Jacksonville, FL 32216 (US).(74) Agents: JOHNSON, Philip, S. et al.; JOHNSON &  
JOHNSON, ONE JOHNSON & JOHNSON PLAZA,  
NEW BRUNSWICK, NJ 08933-7003 (US).(83) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,  
ZW.(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIMICROBIAL CONTACT LENSES CONTAINING ACTIVATED SILVER AND METHODS FOR THEIR PRODUCTION

(57) Abstract: An optically clear antimicrobial lens, containing greater than 0.01 weight percent activated silver is disclosed as well as methods for the production, use, and storage of the lens.

WO 02/062402 A1

WO 02/062402

PCT/US01/50582

## ANTIMICROBIAL CONTACT LENSES CONTAINING ACTIVATED SILVER AND METHODS FOR THEIR PRODUCTION

### RELATED APPLICATIONS

5 This application claims priority from a provisional patent application, U.S. Serial No. 60/257,317 filed on December 21, 2000.

### FIELD OF THE INVENTION

10 This invention relates to optically clear lenses having antimicrobial properties as well as methods of their production, use, and storage.

### BACKGROUND OF THE INVENTION

15 Contact lenses have been used commercially to improve vision since the 1950s. The first contact lenses were made of hard materials. Although these lenses are currently used, they are not suitable for all patients due to their poor initial comfort and their relatively low permeability to oxygen. Later developments in the field gave rise to soft contact lenses, based upon hydrogels, which are extremely popular today. Many users find soft lenses are more comfortable, and increased comfort levels allow soft contact lens users to wear their lenses for far longer hours than users of hard contact lenses.

20 Despite this advantage, the extended use of the lenses can encourage the buildup of bacteria or other microbes, particularly, *Pseudomonas aeruginosa*, on the surfaces of soft contact lenses. The build-up of bacteria or other microbes is not unique to soft contact lens wearer and may occur during the use of hard contact lenses as well.

25 Therefore, there is a need to produce contact lenses which inhibit the growth of bacteria or other microbes and/or the adhesion of bacterial or other microbes on the surface of contact lenses. Further there is a need to produce contact lenses which do not promote the adhesion and/or growth of bacteria or other microbes on the surface of the contact lenses. Also there is a need to  
30 produce contact lenses which inhibit adverse responses related to the growth of bacteria or other microbes.

Others have recognized the need to produce soft contact lenses which inhibit the growth of bacteria. In US Patent No. 5,213,801, the production of an

WO 02/062402

PCT/US01/50582

antibacterial contact lens is disclosed, where an antibacterial metal ceramic material within a soft contact lens is incorporated into a contact lens. This procedure contains a number of steps and may not be suitable for producing all types of lenses in a production environment. The steps include making a silver ceramic material that is fine enough to be used in a contact lens and then forming the lens with the powdered ceramic. However, lenses containing these types of materials often lack the clarity required by contact lens users.

Although these methods and lenses are known, other contact lenses that inhibit the growth and/or adhesion of bacteria or other microbes and are of sufficient optical clarity, as well as methods of making those lenses are still needed. It is this need, which this invention seeks to meet.

#### DETAILED DESCRIPTION OF THE INVENTION

This invention includes an optically clear lens having antimicrobial properties comprising, consisting essentially of, or consisting of, more than about 0.01 weight percent activated silver. As used herein, the phrase "optically clear," refers to a lens that has optical clarity comparable to currently available commercial lenses, e.g. etafilcon A, balafilcon A, and the like. The term "lens" refers to ophthalmic devices that reside in or on the eye. These devices can provide optical correction or may be cosmetic. The term lens includes but is not limited to soft contact lenses, hard contact lenses, intraocular lenses, overlay lenses, ocular inserts, and optical inserts. Typical hard contact lenses are made from polymers which include but are not limited to polymers of poly(methyl)methacrylate, silicone acrylates, fluoroacrylates, fluoroethers, polyacetylenes, and polyimides, where the preparation of representative examples may be found in JP 200010055, JP 6123860, and U.S. Patent 4,330,383. Typical soft contact lenses are made from silicone elastomers, or hydrogels, such as but not limited to silicone hydrogels and fluorohydrogels. The preparation of representative soft contact lenses may be found in US Patent No. 5,710,302, WO 9421698, EP 406161, JP 2000016905, U.S. Pat. No. 5,998,498, US Pat. App. No. 09/532,943, a continuation-in-part of US Pat App. No. 09/532,943, filed on August 30, 2000, and U.S. Patent No. 6,087,415. Examples of commercially available soft contact lenses include but are not limited to etafilcon A, genfilcon A, lenefilcon A, polymacon, and

WO 02/062402

PCT/US01/50582

lotrafilcon A. The preferable contact lenses are etafilcon A, balafilcon A, and silicone hydrogels, as prepared in U.S. Pat. No. 5,998,498, US Pat. App. No. 09/532,943, a continuation-in-part of US Pat App. No. 09/532,943, filed on August 30, 2000, and U.S. Patent No. 6,087,415. Intraocular lenses of the invention can be formed using known materials. For example, the lenses may be made from a rigid material including, without limitation, polymethyl methacrylate, polystyrene, polycarbonate, or the like, and combinations thereof. Additionally, flexible materials may be used including, without limitation, hydrogels, silicone materials, acrylic materials, fluorocarbon materials and the like, or combinations thereof. Typical intraocular lenses are described in WO 0026698, WO 0022460, WO 9929750, WO 9927978, WO 0022459, and JP 2000107277. All of the aforementioned lenses of the invention, may be coated with a number of agents that are used to coat lens. For example, the procedures, compositions, and methods of U.S. Pat. No. 6,087,415 may be used and this patent is hereby incorporated by reference for those procedures, compositions, and methods. All of the references mentioned in this application are hereby incorporated by reference in their entirety.

The term, "activated silver," refers to silver that has been incorporated into the polymer of a lens, prior to forming the lens and subsequently activated by treatment with an oxidizing agent. Oxidizing agents include but are not limited to hydrogen peroxide, sodium hypochlorite, peroxy acids, bromine, chlorine, chromic acid, potassium permanganate, and iodine. The preferred oxidizing agent is sodium hypochlorite. The oxidizing agent can be dispersed or dissolved in an aqueous solution, such as deionized water, and the formed lens may be washed or soaked with this solution for a period of time. The concentration of the oxidizing agent in aqueous solution is about 0.1 to about 60 weight percent, where the percentage is based on the weight (or volume) of the solution, preferably about 0.4 to about 30 weight percent, and more preferably about 0.6 to about 15 weight percent. The period of time for the treating the lenses with the oxidizing agent is about 10 seconds to about 10 hours, preferably about 1 to about 10 minutes.

WO 02/062402

PCT/US01/50582

The silver that is oxidized includes but is not limited to powdered silver having mesh size of -30, -60, or -325 or an average particle size of 2 to 8 microns; nanosize powder; and silver that is formed by reduction of ionic silver in the polymer matrix. The amount of silver in the lens is greater than 0.01 weight percent, where the percentage is based the weight of the components of the un-hydrated monomer. The weight percentage of silver is about 0.01 to about 0.3 weight percent; more preferably, about 0.02 to about 0.2 weight percent, and most preferably about 0.03 to about 0.1 weight percent.

The phrase, "antimicrobial properties," refers to a lenses that exhibit one or more of the following properties, the inhibition of the adhesion of bacteria or other microbes to the lenses, the inhibition of the growth of bacteria or other microbes on lenses, and the killing of bacteria or other microbes on the surface of lenses or in a radius extending from the lenses (hereinafter adhesion of bacteria or other microbes to lenses, the growth of bacteria or other microbes to lenses and the presence of bacterial or other microbes on the surface of lenses is collectively referred to as "microbial production"). Particularly, preferably, the lenses of the invention exhibit at least a 1-log reduction ( $\geq 90\%$  inhibition) of viable bacteria or other microbes, most particularly preferably, about a 2-log reduction ( $\geq 99\%$  inhibition) of viable bacteria or other microbes in in vitro tests. Such bacteria or other microbes include but are not limited to those organisms found in the eye, particularly *Pseudomonas aeruginosa*, *Acanthamoeba*, *Staph. aureus*, *E. coli*, *Staphylococcus epidermidus*, and *Serratia marcescens*.

Further, the invention includes a method of reducing a lens wearer's adverse microbial reactions comprising, consisting essentially of, and consisting of, the step of providing an optically clear lens having antimicrobial properties, the lens comprising, consisting essentially of, or consisting of more than about 0.01 weight percent activated silver. The terms lens, activated silver, optically clear, and antimicrobial properties all have their aforementioned meanings and preferred ranges. The preferred lens wearer is a human. The phrase "adverse events associated with microbial infections" include but are not limited to the following: ulcerative (microbial, infectious) keratitis, infiltrative keratitis, asymptomatic infiltrates, contact lens-induced peripheral ulcer,

WO 02/062402

PCT/US01/50582

contact lens-induced acute red eye, and contact lens-induced papillary conjunctivitis. Although any reduction in the population of bacteria or other microbes in a lens wearer's eye may alleviate the adverse effects associated with microbial infections, it is preferred that the lenses of the invention inhibit the growth of bacteria and other microbes in standard in vitro tests at about 50% to about 100%, more preferably, about 80% to about 100%, most preferably, about 90% to about 100%. Particularly, preferably, the lenses of the invention exhibit at least a 1-log reduction ( $\geq 90\%$  inhibition) of viable bacteria or other microbes, most particularly preferably, about a 2-log reduction ( $\geq 99\%$  inhibition) of viable bacteria or other microbes

Still further, the invention includes a method of producing an optically clear lens having antimicrobial properties, the lens comprising, consisting essentially of, or consisting of, more than about 0.01 weight percent activated silver, where the method comprises, consists essentially of, or consists of treating a lens containing silver with an oxidizing agent. The terms lens, activated silver, optically clear, and antimicrobial properties all have their aforementioned meanings and preferred ranges. The phrase "oxidizing agents" includes but is not limited to hydrogen peroxide, sodium hypochlorite, peroxy acids, bromine, chlorine, chromic acid, potassium permanganate and iodine, where the preferred oxidizing agent is sodium hypochlorite. Although the oxidizing agent can be applied to the lens in a number of ways, preferably it is dispersed or dissolved in an aqueous solution, such as deionized water, and the formed lens may be washed or soaked with this solution for a period of time. The concentration of the oxidizing agent in aqueous solution is about 0.1 to about 50 weight percent, preferably about 0.4 to about 30 weight percent, and more preferably about 0.6 to about 15 weight percent, where the percentage is based on the weight of the solution. The period of time for the treating the lenses with the oxidizing agent is about 10 seconds to about 10 hours, preferably about 1 to 10 minutes.

Yet still further, the invention includes a lens case having antimicrobial properties, comprising, consisting essentially of, or consisting of, more than about 0.01 weight percent activated silver. The terms lens, activated silver, optically clear, and antimicrobial properties all have their aforementioned

WO 02/062402

PCT/US01/50582

meanings and preferred ranges. The term lens case refers to a container that is adapted to define a space in which to hold a lens when that lens is not in use. This term includes packaging for lenses, where packaging includes any unit in which a lens is stored after curing. Examples of this packaging include  
5 but are not limited to single use blister packs and the like.

One such container is illustrated in Figure 3 of U.S. Pat. 5,515,117 which is hereby incorporated by reference in its entirety. Silver can be incorporated in the lens container 22, the cover 24, or the lens basket 26, where they are preferably incorporated into the lens container or the lens  
10 basket. (numbers refer to U.S. Pat. 5,515,117) The silver within such lens cases can be activated by the same methods described for the lenses of the invention.

Aside from activated silver, the container components may be made of a transparent, thermo-plastic polymeric material, such as  
15 polymethylmethacrylate, polyolefins, such as poly-ethylene, polypropylene and the like; polyesters, polyurethanes; acrylic polymers, such as polyacrylates and polymethacrylates; polycarbonates and the like and is made, e.g., molded, using conventional techniques as a single unit.

Storing lenses in such an environment inhibits the growth of bacteria on  
20 said lenses and adverse effects that are caused by the proliferation of bacterial. Another example of such a lens case is the lens case can be found in U.S. Pat. No. 6,029,808 which is hereby incorporated by reference for the blister pack housing for a contact lens disclosed therein.

Either the lens container, the lens basket or the top may contain  
25 activated silver. In the same manner as the lenses of the invention, silver can be added to the monomer mix of the other components. The resulting mixture is charged to molds, cured, and subsequently treated with an oxidizing agent. The method of treating the molded article with an oxidizing agent is analogous to the method described for the treatment of formed lenses to give lenses with  
30 activated silver. Preferably, activated silver is present in any or all of the lens case components at about 0.01 to about 10 weight percent (based on the initial monomer mix), more preferably about 0.05 to about 3.0 percent.

WO 02/062402

PCT/US01/50582

In order to illustrate the invention the following examples are included. These examples do not limit the invention. They are meant only to suggest a method of practicing the invention. Those knowledgeable in contact lenses as well as other specialties may find other methods of practicing the invention.

5 However, those methods are deemed to be within the scope of this invention.

### EXAMPLES

The following abbreviations are used in the examples below:

	HEMA	2-hydroxyethyl methacrylate
10	BAGE	glycerin esterified with boric acid
	EGDMA	ethyleneglycol dimethacrylate
	Darocur™ 1173	2-hydroxy-2-methyl-1-phenyl-propan-1-one
	MAA	methacrylic acid
	TRIS	3-methacryloxypropyltris (trimethylsiloxy) silane
15	DMA	N,N-dimethylacrylamide
	THF	tetrahydrofuran
	TMI	dimethyl meta-isopropenyl benzyl isocyanate
	HEMA	2-hydroxyethyl methacrylate
	TEGDMA	tetraethyleneglycol dimethacrylate
20	MMA	methyl methacrylate
	TBACB	tetrabutyl ammonium-m-chlorobenzoate
	mPDMS	800-1000 MW monomethacryloxypropyl terminated polydimethylsiloxane
	3M3P	3-methyl-3-pentanol
25	Norbloc	2-(2'-hydroxy-5-methacryloxyethylphenyl)-2H-benzotriazole
	CGI 1850	1:1 (wgt) blend of 1-hydroxycyclohexyl phenyl ketone and bis(2,6-dimethoxybenzoyl)-2,4,4-trimethylpentyl phosphine oxide
	PVP	poly(N-vinyl pyrrolidone)
30	IPA	isopropyl alcohol
	GMMA	glycerin 1-monomethacrylate
	mPEG 350	poly(ethylene glycol) methyl ether



WO 02/062402

PCT/US01/50582

D3O 3,7-dimethyl-3-octanol  
TAA t-amyl alcohol  
Blue HEMA the reaction product of reactive blue number 4 and HEMA,  
as described in Example 4 or U.S. Pat. no. 5,944,853

5 Biological Vortex Assay

The following viable bacteria adhesion assay was used where indicated in the following examples. A culture of *Pseudomonas aeruginosa*, ATCC# 15442 (ATCC, Rockville, MD) is grown overnight in a nutrient medium. The bacterial inoculum is prepared to result in a final concentration of  $1 \times 10^8$  colony forming units (cfu)/ml. Three contact lenses are rinsed with phosphate buffered saline ("PBS") pH  $7.4 \pm 0.2$ . Each washed contact lens is combined with two ml of the bacterial inoculum into a glass vial, which is agitated in a shaker-incubator for two hr. at  $37 \pm ^\circ\text{C}$ . Each lens is washed with PBS, placed into 10 ml of PBS containing 0.05% Tween™ 80 and vortexed at 2000 rpm for three min. The resulting supernatant is enumerated for viable bacteria, and the results of the detected viable bacteria attached to three lenses are averaged.

WO 02/062402

PCT/US01/50582

### Example 1

A blend of 9.80 g HEMA, 0.08 g EGDMA, 0.04 g Darocur™ 1173, and nanosize activated powdered silver (99.9+%, from Aldrich Chemicals), in 9.80 g of BAGE diluent, was sonicated for 1 hour. The resulting mixture was charged to a mold subsequently exposed to UV light for 30 minutes in a polystyrene to cure the polymer. After curing, the molds were opened, and the lenses were washed out into borate-buffered saline. The resulting lenses were soaked for 10 minutes in a 5.25% v/v solution of sodium hypochlorite in water, then rinsed 5 times in 0.85% v/v physiological saline solution. The number of viable *Pseudomonas aeruginosa* adhered to the lenses using the microbial assay described above was reduced by 99.8% compared to the untreated contact lens.

### Examples 2-4

The procedure of Example 1 was repeated, with addition of MAA as indicated in Table 1. In all cases the adhesion of viable bacteria was reduced when compared to a lens of the same polymer composition without silver. The results of the biological assay are shown in Table 1.

Table 1

	Example 1	Example 2	Example 3	Example 4
HEMA, g	9.80	9.80	9.80	9.80
MAA, g	0.00	0.06	0.14	0.20
EGDMA, g	0.08	0.08	0.08	0.08
Darocur 1173, g	0.04	0.04	0.04	0.04
Nanosize Ag	0.022	0.022	0.022	0.022
Reduction in viable bacteria*	99.8%	99.7%	99.7%	99.7%

WO 02/062402

PCT/US01/50582

## Example 5

Macromer B Preparation

To a dry container housed in a dry box under nitrogen at ambient temperature was added 30.0 g (0.277 mol) of bis(dimethylamino)methylsilane, a solution of 13.75 ml of a 1M solution of TBACB (386.0 g TBACB in 1000 ml dry THF), 61.39 g (0.578 mol) of p-xylene, 154.28 g (1.541 mol) methyl methacrylate (1.4 equivalents relative to initiator), 1892.13 g (9.352 mol) 2-(trimethylsiloxy)ethyl methacrylate (8.5 equivalents relative to initiator) and 4399.78 g (61.01 mol) of THF. To a dry, three-necked, round-bottomed flask equipped with a thermocouple and condenser, all connected to a nitrogen source, was charged the above mixture prepared in the dry box.

The reaction mixture was cooled to 15 °C while stirring and purging with nitrogen. After the solution reaches 15 °C, 191.75 g (1.100 mol) of 1-trimethylsiloxy-1-methoxy-2-methylpropene (1 equivalent) was injected into the reaction vessel. The reaction was allowed to exotherm to approximately 62 °C and then 30 ml of a 0.40 M solution of 154.4 g TBACB in 11 ml of dry THF was metered in throughout the remainder of the reaction. After the temperature of reaction reached 30 °C and the metering began, a solution of 467.56 g (2.311 mol) 2-(trimethylsiloxy)ethyl methacrylate (2.1 equivalents relative to the initiator), 3636.6 g (3.463 mol) n-butyl monomethacryloxypropylpolydimethylsiloxane (3.2 equivalents relative to the initiator), 3673.84 g (8.689 mol) TRIS (7.9 equivalents relative to the initiator) and 20.0 g bis(dimethylamino)methylsilane was added.

25

The mixture was allowed to exotherm to approximately 38-42 °C and then allowed to cool to 30 °C. At that time, a solution of 10.0 g (0.076 mol) bis(dimethylamino)methylsilane, 154.26 g (1.541 mol) methyl methacrylate (1.4 equivalents relative to the initiator) and 1892.13 g (9.352 mol) 2-trimethylsiloxy)ethyl methacrylate (8.5 equivalents relative to the initiator) was added and the mixture again allowed to exotherm to approximately 40 °C. The reaction temperature dropped to approximately 30 °C and 2 gallons of THF were added to decrease the viscosity. A solution of 439.69 g water, 740.6 g

30

WO 02/062402

PCT/US01/50582

methanol and 8.8 g (0.068 mol) dichloroacetic acid was added and the mixture refluxed for 4.5 hours to de-block the protecting groups on the HEMA. Volatiles were then removed and toluene added to aid in removal of the water until a vapor temperature of 110 °C was reached.

5

The reaction flask was maintained at approximately 110 °C and a solution of 443 g (2.201 mol) TMI and 5.7 g (0.010 mol) dibutyltin dilaurate were added. The mixture was reacted until the isocyanate peak was gone by IR. The toluene was evaporated under reduced pressure to yield an off-white, anhydrous, waxy reactive monomer. The macromer was placed into acetone at a weight basis of approximately 2:1 acetone to macromer. After 24 hrs, water was added to precipitate out the macromer and the macromer was filtered and dried using a vacuum oven between 45 and 60 °C for 20-30 hrs.

10

#### 15 Lens Formation

A hydrogel was made from the following monomer mix (all amounts are calculated as weight percent of the total weight of the combination): macromer B (~18%), mPDMS (~28%), TRIS (~14%), DMA (~26%), HEMA (~5%), TEGDMA (~1%), PVP (~5%); CGI 1850 (~1%), glacial acetic acid (~5%), nanosize activated powdered silver (from Aldrich Chemicals ~0.13%), with the balance comprising minor amounts of additives. The polymerization was conducted in the presence of 20%wt dimethyl-3-octanol diluent, and the blend was sonicated for 30 minutes before curing.

20

Contact lenses were formed by adding about 0.10 g of the monomer mix to the cavity of an eight-cavity lens mold of the type described in U.S. Patent 4,640,489. The lenses were cured for 8 minutes at 50 °C (±5) using visible light (wavelength: 380-460 nm with a peak maximum at 425 nm, dose: approx. 2.5 J/cm<sup>2</sup>). After curing, the molds were opened, and the lenses were released into a 1:1 blend of water and ethanol, then leached in ethanol to remove any residual monomers and diluent. Finally the lenses were equilibrated in physiological borate-buffered saline. The lenses appeared transparent when examined with the naked eye, although the silver particles could be seen under

25

30

WO 02/062402

PCT/US01/50582

magnification. The resulting lenses were soaked for 21 hours in a 5.25% solution of sodium hypochlorite in water, then rinsed 5 times in saline solution. The lenses were tested for antibacterial properties by the following method:

#### 5 Biological Broth Assay

Each lens was washed with Dulbecco's Phosphate Buffered Saline without calcium chloride and magnesium chloride, then placed into 1000  $\mu$ l of Mueller Hinton Broth containing  $10^8$  cfu/ml *Pseudomonas aeruginosa* (ATCC 15442), and incubated at 37°C overnight. The resulting solutions were  
10 observed for opacity and cultured to enumerate the bacteria, and compared to similar lenses that were not reacted with sodium hypochlorite. The results, in Table 3, show that the number of bacteria were reduced by >99.99%.

Table 3

	Example 5 lens	Lenses without sodium hypochlorite
Solution clarity	Clear	Opaque
Bacteria count cfu/ml	$3.8 \times 10^4$	$6.2 \times 10^8$

15

#### Example 6-8

A blend was made of 40.67 weight % HEMA, 1.0% Darocur 1173, 1.07% TEGDMA, 26.90% GMMA and 30.36% mPEG 350 (diluent). Nanosize activated powdered silver was added to this blend in amounts indicated in  
20 Table 4. Lenses were made and treated with sodium hypochlorite following the procedure of Example 1.

Lenses were autoclave sterilized, and tested for their antibacterial properties using the microbial assay described directly above. The results are shown in Table 4.

WO 02/062402

PCT/US01/50582

Table 4

	Silver particles in blend	% Reduction in bacteria number*
Example 6	0.05 weight %	99.7%
Example 7	0.10 weight %	99.8%
Example 8	0.15 weight %	99.6%

\*As compared to lenses of the same composition made without silver.

WO 02/062402

PCT/US01/50582

## Examples 9-12

Lenses were made using the blend and method described in Example 5, except without addition of powdered silver, and without reacting with sodium hypochlorite. These lenses were rinsed with deionized water to remove chloride ions. They were soaked in varying concentrations of  $\text{AgNO}_3$ , as indicated in Table 4 for 30 minutes, blotted to remove surface water, and placed into a solution of 5.0% ascorbic acid in water. After one hour the lenses were rinsed in deionized water, and then soaked either in 5.25% sodium hypochlorite or 3.0% aqueous hydrogen peroxide for 10 minutes or 60 minutes respectively, as indicated in Table 5. The lenses were rinsed in borate-buffered saline, autoclave sterilized, and tested for antibacterial properties using the vortex assay described above. The results are shown in Table 5

Table 5

	$[\text{AgNO}_3]$	Oxidant	Oxidation time	% Reduction in bacteria number
EXAMPLE 9	$10^{-1}\text{M}$	5.25% NaOCl	10 minutes	99.9%
EXAMPLE 10	$10^{-2}\text{M}$	5.25% NaOCl	10 minutes	99.9%
EXAMPLE 11	$10^{-3}\text{M}$	5.25% NaOCl	10 minutes	99.9%
EXAMPLE 12	$10^{-3}\text{M}$	3.0% $\text{H}_2\text{O}_2$	60 minutes	99.2%

As compared with a lens made without silver or oxidation.

## EXAMPLES 13-16

The lenses of Example 5 were made, but with 0.10% nanosize silver, and instead of reacting with sodium hypochlorite, reacting with a solution of 3.0% hydrogen peroxide diluted to the indicated concentration with borate-buffered saline at room temperature for the time indicated in Table 6. The lenses were tested using the microbial assay described above. The results are shown in Table 6.

WO 02/062402

PCT/US01/50582

Table 6

	Oxidant	Oxidation time	% Reduction in bacteria number*
EXAMPLE 13	1.5% H <sub>2</sub> O <sub>2</sub>	10 minutes	96%
EXAMPLE 14	1.5% H <sub>2</sub> O <sub>2</sub>	30 minutes	98%
EXAMPLE 15	1.5% H <sub>2</sub> O <sub>2</sub>	60 minutes	98%
EXAMPLE 16	0.75% H <sub>2</sub> O <sub>2</sub>	60 minutes	99%

\*Compared to lenses of the same composition and are treated with H<sub>2</sub>O<sub>2</sub>, but made without silver.

5

## Examples 17-19

The lenses of Example 5 were made, but with 0.10% nanosize silver, and instead of reacting with sodium hypochlorite, reacting with a solution of 50% hydrogen peroxide diluted as needed to the indicated concentration with borate-buffered saline at room temperature for the time indicated in Table 7. The lenses were tested using the vortex assay described above. The results are shown in Table 7.

Table 7

	Oxidant	Oxidation time	% Reduction in bacteria number*
EXAMPLE 17	3.0% H <sub>2</sub> O <sub>2</sub>	60 minutes	96%
EXAMPLE 18	10.0% H <sub>2</sub> O <sub>2</sub>	60 minutes	94%
EXAMPLE 19	50.0% H <sub>2</sub> O <sub>2</sub>	60 minutes	91%

\*Compared to lenses of the same composition and are treated with H<sub>2</sub>O<sub>2</sub>, but made without silver.

15



WO 02/062402

PCT/US01/50582

## EXAMPLES 20-22

The lenses of EXAMPLE 5 were made, but instead of reacting with sodium hypochlorite, reacting with an aqueous solution of 0.05M I<sub>2</sub> and 0.20 M KI at room temperature for the time indicated in Table 8. The lenses were tested using the vortex assay described above. The results are shown in Table 8.

Table 8

	Oxidant	Oxidation time	% Reduction in bacteria number*
Example 20	0.05M I <sub>2</sub>	15 minutes	80%
Example 21	0.05M I <sub>2</sub>	60 minutes	90%
Example 22	0.05M I <sub>2</sub>	1620 minutes	92%

\*Compared to an etafilcon A lens. The antibacterial activity of etafilcon A lenses is statistically the same as the activity of the lenses of example 5, when prepared without silver (95% confidence (p=0.09)).

## EXAMPLES 23-25

The lenses of EXAMPLE 5 were made, but with 0.20% nanosize silver, and instead of reacting with sodium hypochlorite, reacting with a solution of 3.0% hydrogen peroxide diluted to the indicated concentration with borate-buffered saline at room temperature for the time indicated in Table 9. The lenses were tested using the vortex assay described above. The results are shown in Table 9.

Table 9

	Oxidant	Oxidation time	% Reduction in bacteria number*
EXAMPLE 23	1.5% H <sub>2</sub> O <sub>2</sub>	10 minutes	93%
EXAMPLE 24	1.5% H <sub>2</sub> O <sub>2</sub>	60 minutes	90%
EXAMPLE 25	1.5% H <sub>2</sub> O <sub>2</sub>	1440 minutes	92%

\*Compared to a similar H<sub>2</sub>O<sub>2</sub>-reacted lens made without silver.

WO 02/062402

PCT/US01/50582

## Examples 26-35

Nanosize silver can be added to the compositions listed in Table 10. Subsequently, lenses can be prepared as described in Example 5 and oxidized with 1-2 wgt.% H<sub>2</sub>O<sub>2</sub>. Macromers A and C were prepared as follows:

## Macromer A:

The procedure for Macromer B used except that 19.1 mole parts HEMA, 5.0 mole parts MAA, 2.8 mole parts MMA, 7.9 mole parts TRIS, 3.3 mole parts mPDMS, and 2.0 mole parts TMI were used.

## Macromer C:

The procedure for Macromer B was used except that 19.1 mole parts HEMA, 7.9 mole parts TRIS, 3.3 mole parts mPDMS, and 2.0 mole parts TMI were used.

Table 10

EXAMPLE	26	27	28	29	30	31	32	33	34	35
Macromer	A	B	C	C	B	B	B	B	B	B
Macromer	30.00	25.00	60.00	20.00	17.98	17.98	19.98	17.98	17.98	19.98
TRIS	0.00	18.00	0.00	40.00	21.00	21.00	8.00	20.00	25.00	20.00
DMA	27.00	28.00	36.00	36.00	25.50	25.50	26.00	22.00	9.00	23.00
mPDMS	39.00	18.00	0.00	0.00	21.00	21.00	28.50	25.50	30.00	28.50
Norbloc	2.00	2.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00
CGI 1850	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
TEGDMA	0.00	0.00	0.00	0.00	1.50	1.50	1.50	1.50	0.50	1.50
HEMA	0.00	0.00	0.00	0.00	5.00	5.00	5.00	5.00	7.00	5.00
Blue HEMA	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.02	0.02	0.02
PVP	0.00	8.00	0.00	0.00	5.00	5.00	8.00	5.00	7.50	9.00
Diluent %	41	20	20	None	20	50.00	37.50	20.00	40.00	50.00
Diluent	3M3P	3M3P	3M3P	NA	D3O	TAA	3M3P	TAA	3M3P	3M3P

WO 02/062402

PCT/US01/50582

What is claimed is:

1. An optically clear lens having antimicrobial properties comprising more than about 0.01 weight percent activated silver.
- 5 2. The lens of claim 1 wherein, the lens is a soft contact lens.
3. The lens of claim 1 wherein, the lens is a silicone hydrogel.
4. The lens of claim 1 having about 0.02 to about 0.2 weight percent  
10 activated silver.
5. The lens of claim 1 having about 0.05 to about 0.2 weight percent activated silver.
- 15 6. The lens of claim 1 wherein, the lens is a silicone hydrogel having about 0.02 to about 0.1 weight percent activated silver.
7. The lens of claims 6, 5, or 4 wherein the lens is lenefilcon A, aquafilcon A, etafilcon A, genfilcon A, balafilcon A, polymacon, or lotrafilcon A.
- 20 8. A method of reducing a lens wearer's adverse microbial reactions comprising, the step of providing an optically clear lens having antimicrobial properties, the lens comprising more than about 0.01 weight percent activated silver.
- 25 9. The method of claim 8 wherein the lens is a contact lens.
10. The method of claim 8 wherein, the lens has about 0.02 to about 0.2 weight percent activated silver.
- 30 11. The method of claim 8 wherein, the lens is a silicone hydrogel having about 0.05 to about 0.1 percent activated silver.

WO 02/062402

PCT/US01/50582

12. A method of producing an optically clear lens having antimicrobial properties comprising more than about 0.01 weight percent activated silver, where the method comprises the step of, treating a lens containing silver with an oxidizing agent.
- 5
13. The method of claim 12 wherein, the oxidizing agent is selected from the group consisting of hydrogen peroxide, sodium hypochlorite, peroxy acids, bromine, chlorine, chromic acid, potassium permanganate and iodine.
- 10
14. The method of claim 12 wherein the oxidizing agent is sodium hypochlorite.
- 15
15. A lens case having antimicrobial properties comprising more than about 0.01 weight percent activated silver.
16. The lens case of claim 15, wherein at least one component of the case has about 0.05 to about 3 weight percent activated silver.

## INTERNATIONAL SEARCH REPORT

Information Application No

PCT/US 01/50582

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G02C7/04 G02B1/04 A61L27/02 A61L27/14 A61L12/08  
A45C11/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G02C G02B A61L A45C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NISSEN S ET AL: "Antimicrobial efficacy of a silver layer on hydrogel lenses! Citation!" DER OPHTHALMOLOGE: ZEITSCHRIFT DER DEUTSCHEN OPHTHALMOLOGISCHEN GESELLSCHAFT. GERMANY SEP 2000, vol. 97, no. 9, September 2000 (2000-09), pages 640-643, XP002204043 ISSN: 0941-293X abstract	1-11
Y		12-14
X	EP 1 050 314 A (HEALTHSHIELD TECHNOLOGIES L L) 8 November 2000 (2000-11-08) column 3, line 37 - line 44 column 4, line 26 - line 32 column 5, line 8 - line 47	1-11
Y	column 5, line 8 - line 47	12-14

-/-

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*S\* document member of the same patent family

Date of the actual completion of the international search

1 July 2002

Date of mailing of the international search report

15/07/2002

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentplan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2060, Tx. 31 651 cpo nl  
Fax (+31-70) 340-2016

Authorized officer

Jochheim, J

Form PCT/ISA210 (second sheet) (July 1992)

page 1 of 2

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/50582

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 18330 A (SURFACINE R CONSUMER PRODUCTS ;BIOPOLYMERIX INC (US)) 7 May 1998 (1998-05-07) claims 34,36; examples 1,2	15,16
Y	US 5 312 586 A (STOCKEL RICHARD F) 17 May 1994 (1994-05-17) claims 1,3	12-14
A	WO 00 38552 A (HEALTHSHIELD TECHNOLOGIES LLC) 6 July 2000 (2000-07-06) page 3, line 20 - line 27	15,16
A	US 5 515 117 A (ANGER CLAUDE B ET AL) 7 May 1996 (1996-05-07) column 8, line 38 - line 47	1-16

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

page 2 of 2

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/50582

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 1050314	A	08-11-2000	CA	2308256 A1	07-11-2000
			EP	1050314 A1	08-11-2000
WO 9818330	A	07-05-1998	US	5849311 A	15-12-1998
			US	5817325 A	06-10-1998
			AU	723898 B2	07-09-2000
			AU	5088898 A	22-05-1998
			EP	0939591 A1	08-09-1999
			JP	2001508041 T	19-06-2001
			TW	381029 B	01-02-2000
			WO	9818330 A1	07-05-1998
			US	6264936 B1	24-07-2001
			US	6126931 A	03-10-2000
US 5312586	A	17-05-1994	US	5366694 A	22-11-1994
WO 0038552	A	06-07-2000	AU	2217900 A	31-07-2000
			WO	0038552 A1	06-07-2000
US 5515117	A	07-05-1996	US	5340583 A	23-08-1994
			AU	6905794 A	12-12-1994
			CA	2162148 A1	24-11-1994
			EP	0697115 A1	21-02-1996
			JP	8510340 T	29-10-1996
			WO	9427170 A1	24-11-1994

Form PCT/ISA/210 (patent family annex) (July 1992)